Organon & Co. (LON: 0A9W)
London
· Delayed Price · Currency is GBP · Price in USD
15.65
-0.50 (-3.10%)
At close: Jan 31, 2025
Organon & Co. Revenue
Organon & Co. had revenue of $1.58B USD in the quarter ending September 30, 2024, with 4.15% growth. This brings the company's revenue in the last twelve months to $6.41B, up 4.21% year-over-year. In the year 2023, Organon & Co. had annual revenue of $6.26B with 1.44% growth.
Revenue (ttm)
$6.41B
Revenue Growth
+4.21%
P/S Ratio
n/a
Revenue / Employee
$640.90K
Employees
10,000
Market Cap
3.22B GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
Shell | 227.10B |
HSBC Holdings | 43.25B |
Unilever | 51.12B |
Rio Tinto Group | 42.87B |
RELX PLC | 9.30B |
British American Tobacco p.l.c. | 26.18B |
BP p.l.c. | 144.69B |
Organon & Co. News
- 10 days ago - Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025 - Business Wire
- 16 days ago - Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield - Seeking Alpha
- 19 days ago - Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript) - Seeking Alpha
- 22 days ago - Organon snaps six days of winning streak - Seeking Alpha
- 6 weeks ago - Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 6 weeks ago - Organon gets expanded FDA approval for VTAMA - Seeking Alpha
- 6 weeks ago - Organon & Co (OGN) Secures FDA Approval for VTAMA Cream in Treating Atopic Dermatitis - GuruFocus
- 6 weeks ago - FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older - Benzinga